Creatine phosphokinase enzyme elevation in two third-level hospitals of Córdoba
Creatine phosphokinase enzyme elevation
DOI:
https://doi.org/10.31053/1853.0605.v79.n4.36031Keywords:
creatine phosphokinase, muscular diseases, myositis, inflammationAbstract
Introduction: HyperCKemia is defined as the elevation of creatine phosphokinase (CK) levels greater than 1.5 times the upper limit (CK>285 U/L), being produced by multiple causes, which vary according different populations. The main objective of the study was to know the frequency of hyperCKemia in two hospitals in Córdoba and its main causes.
Methods: Retrospective analytical study in two hospitals in Córdoba, Argentina, where all patients over 18 years of age who presented CK values greater than 285 U/L on at least 2 occasions in a period between 1 and 4 weeks were identified, between the years 2015 and 2017.
Results: 254 patients with hyperCKemia were identified, the majority were male (n=181, 71.3%) and their median age was 65 years (interquartile range 25-75%=50-73 years). The main causes of hyperCKemia were ischemic myopathy in 99 (39%) patients and drug-induced myopathies in 45 (17.7%), with statins being the most frequently involved drugs in 31 cases. In only 3.1% of the cases the final diagnosis was not reached. Drug-induced hyperCKemias, when compared to other causes, occurred more frequently in patients with a history of chronic kidney disease (9/45 [20%] vs 18/209 [8.6%], p = 0.025) and in non-smokers (41/45 [91.1%] vs. 157/209 [75.1%], p=0.019).
Main conclusion: 254 cases of hyperCKemia were observed, the main causes being of ischemic origin and secondary to drug use, especially statins.
Downloads
References
Venance SL. Approach to the Patient With HyperCKemia. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1803-1814. doi: 10.1212/01.CON.0000511069.68640.39.
D’Ottavio GE, Parodi R, Montero JE, Egri N, Carlson D, Greca A. Creatinfosfoquinasa y su aplicación clínica. Anuario Fundación Dr JR Villavicencio 2008;16:156-159.
Chawla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011 Aug 5;2:49. doi: 10.3389/fneur.2011.00049.
Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests: Lippincott Williams & Wilkins, 2009.
Morandi L, Angelini C, Prelle A, Pini A, Grassi B, Bernardi G, Politano L, Bruno C, De Grandis D, Cudia P, Citterio A. High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm. Neurol Sci. 2006 Nov;27(5):303-11. doi: 10.1007/s10072-006-0701-0.
Earle N, Bevilacqua JA. Distrofias musculares en el paciente adulto. Revista Médica Clínica Las Condes 2018;29(6):599-610. doi: 10.1016/j.rmclc.2018.08.006
Dugué A, Bagheri H, Lapeyre-Mestre M, Tournamille JF, Sailler L, Dedieu G, Salvayre R, Thouvenot JP, Massip P, Montastruc JL. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur J Clin Pharmacol. 2004 Jun;60(4):285-92. doi: 10.1007/s00228-004-0760-1.
Parra AV, Fernández DC, Latorre JM, Díaz JG. Protocolo diagnóstico de la hiperCKemia persistente. Medicine-Programa de Formación Médica Continuada Acreditado 2016;12(19):1116-1120. doi: 10.1016/j.med.2016.09.024
Kyriakides T, Angelini C, Schaefer J, Sacconi S, Siciliano G, Vilchez JJ, Hilton-Jones D; European Federation of Neurological Societies. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010 Jun 1;17(6):767-73. doi: 10.1111/j.1468-1331.2010.03012.x.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789.
Amir KA, Chen SX, Bobba RK, Arsura EL. Elevation of serum creatine phosphokinase in hospitalized patients. Am J Med Sci. 2009 Nov;338(5):353-6. doi: 10.1097/MAJ.0b013e3181b1226a.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959.
Sociedad Argentina de Cardiología. Área de Normatizaciones y Consensos. Consenso de Prevención Cardiovascular. Rev Argent Cardiol 2012;80(Supl 2):1-127.
Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002 May 21;105(20):2341-6. doi: 10.1161/01.cir.0000017634.00171.24.
Prisant LM, Downton M, Watkins LO, Schnaper H, Bradford RH, Chremos AN, Langendörfer A. Efficacy and tolerability of lovastatin in 459 African-Americans with hypercholesterolemia. Am J Cardiol. 1996 Aug 15;78(4):420-4. doi: 10.1016/s0002-9149(96)00330-x.
Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001 Nov 5;175(9):486-9. doi: 10.5694/j.1326-5377.2001.tb143683.x.
Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007 Jan;19(1):67-73. doi: 10.1097/BOR.0b013e328010c559.
Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009 Oct;22(5):506-15. doi: 10.1097/WCO.0b013e32833045a0.
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. doi: 10.1056/NEJMra041867. Erratum in: N Engl J Med. 2007 Jun 7;356(23):2437. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714.
Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000 Jul;79(4):201-9. doi: 10.1097/00005792-200007000-00001.
Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998 Jul;19(1):73-82. doi: 10.2165/00002018-199819010-00006.
Manero Marcén E, Malo Ocejo P, Uriarte Uriarte JJ, Pinilla Tubet E. Estudio de la creatinfosfokinasa en una población psiquiátrica hospitalaria [Creatine phosphokinase in a hospitalized psychiatric population]. Arch Neurobiol (Madr). 1992 Sep-Oct;55(5):235-40.
Bevilacqua JA, Earle N. Miopatías inflamatorias. Revista Médica Clínica Las Condes 2018;29(6):611-621. doi: 10.1016/j.rmclc.2018.09.002.
Young P, Quintana JJ, Pardal A, Bruetman JE, Finn BC, Reisin RC. Enfoque del paciente con hiperckemia persistente. Fronteras en Medicina 2014;9(3):71-82. doi: 10.31954/RFEM/2014003/0071-0082
Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016 Jan;83(1):37-42. doi: 10.3949/ccjm.83a.14120.
Silvestri NJ, Wolfe GI. Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia). Muscle Nerve. 2013 Jun;47(6):805-15. doi: 10.1002/mus.23755.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
